Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Linda Ahn, Terri Alexander, Soetkin Vlassak and 2 others
PMID 36108212WHAT IT FOUND
Tepotinib adverse events are mostly mild to moderate, but nurses should proactively monitor for leg swelling, nausea, diarrhea, creatinine and liver changes, and respiratory symptoms.
Early recognition and patient education can help reduce treatment interruptions.
Key findings
01In 255 patients with MET exon 14 skipping NSCLC, tepotinib treatment-related adverse events occurred in 86% of patients and Grade 3 or higher events occurred in 24%.
02Peripheral edema was the most common treatment-related adverse event, reported in 54% of patients, and most edema events were mild or moderate.
03Treatment-related adverse events led to dose reduction in 28% of patients and interruption in 35%, with permanent discontinuation in 11%.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
It is a narrative review and guidance article, not a controlled trial. Recommendations are based on published evidence, prescribing information, and nursing experience. The case studies are illustrative and do not prove that a management strategy works. Safety data are from the VISION trial population, which was mostly elderly with advanced disease.
The easy way to misread this
Do not read this as proof that the recommended management strategies improve outcomes, because the article is a review and guidance piece, not a controlled trial. A creatinine rise should not be assumed to mean kidney damage, and suspected interstitial lung disease requires prompt interruption and evaluation.